Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects

Results from a six month randomized controlled trial

authored by

Jan Philipp Schuchardt, J. Neubronner, G. Kressel, M. Merkel, C. von Schacky, A. Hahn

Abstract

Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01 g EPA+0.67 g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.

Organisation(s)

Institute of Food Science and Human Nutrition
Nutrition Physiology and Human Nutrition Section

External Organisation(s)

Asklepios Klinik St. Georg
Ludwig-Maximilians-Universität München (LMU)

Type

Article

Journal

Prostaglandins Leukotrienes and Essential Fatty Acids

Volume

85

Pages

381-386

No. of pages

6

ISSN

0952-3278

Publication date

12.2011

Publication status

Published

Peer reviewed

Yes

ASJC Scopus subject areas

Clinical Biochemistry, Cell Biology

Electronic version(s)

https://doi.org/10.1016/j.plefa.2011.07.006 (Access: Unknown)